AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. CellSource Co.,Ltd.
  3. Financials
  4. EBITDA

CellSource Co.,Ltd.【JP:4880】

Market cap
¥7.5B
P/E ratio
-54.8x
CellSource processes blood and fat tissue into therapeutic substances for medical institutions offering regenerative medicine treatments like knee osteoarthritis and infertility care.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Oct 31, 2025365+34.60%
Oct 31, 2024271-78.90%
Oct 31, 20231,285-20.48%
Oct 31, 20221,616+58.02%
Oct 31, 20211,023+131.54%
Oct 31, 2020442+27.08%
Oct 31, 2019348+12.73%
Oct 31, 2018308

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)